Skip to main content

Beta amyloid oligomers in the early diagnosis of AD and as marker for treatment response

Objective

Alzheimer's disease (AD) is one of the most common neurodegenerative disorders, which currently affects 4 million subjects in the European Union. The prevalence of AD is expected to increase substantially the next decades due to the aging population. AD severely affects the quality of life of patients and their relatives. It also poses a major burden to the health care system. Abnormalities in beta amyloid processing are a key feature of the disease. Therapeutic strategies, which modify beta amyloid processing, are currently under development. The development of these drugs, however, is hampered by the lack of accurate diagnostic criteria for AD in the early stage and the lack of potential markers of treatment response. Recent studies indicated that beta amyloid oligomers play an important role in the early pathophysiology of AD. The aim of the present project is to investigate whether beta amyloid oligomers in cerebrospinal fluid, plasma, and serum can be used for the early diagnosis of AD and whether they can be used as a marker of treatment response. In it will be investigated whether genes known to be involved in beta amyloid processing influence levels of these markers.Oligomers will be measured using two techniques. The first is based on ultrasensitive immuno-polymerase chain reaction and will be developed during the project. The second is based on a combination of immunoprecipitation and ELISA and has already been developed by one of the partners. Measurements will be performed in cerebrospinal fluid, serum, and plasma samples of 100 subjects with AD, 250 subjects with mild cognitive impairment (a prodromal stage of AD), 100 subjects with other types of dementia, and 50 control subjects. In order to investigate the potential of beta amyloid oligomers to be used as marker of treatment response, cerebrospinal fluid samples and blood samples will be collected 9 and 18 months after baseline in 60 subjects with AD and 60 with mild cognitive impair

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Coordinator

VRIJE UNIVERSITEIT MEDICAL CENTRE
Address
De Boelelaan 1117
Amsterdam
Netherlands

See on map

Participants (13)

CHIMERA BIOTECH GMBH
Germany
Address
Kurfürstenallee 23a
Bremen

See on map

HYCULT BIOTECHNOLOGY B.V.
Netherlands
Address
Frontstraat 2a, 5405 Pb
Uden

See on map

ACADEMISCH MEDISCH CENTRUM/UNIVERSITEIT VAN AMSTERDAM
Netherlands
Address
Meibergdreef 9
Amsterdam

See on map

Links
KAROLINSKA INSTITUTET
Sweden
Address
Inst Neurotec, Karolinska Universitetssjukhuset, Novum Plan 5
Huddinge

See on map

Links
ARISTOTLE UNIVERSITY OF THESSALONIKI
Greece
Address
Administration Building - University Campus
Thessaloniki

See on map

KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
Address
Oude Markt 13
Leuven

See on map

RIGSHOSPITALET
Denmark
Address
Blegdamsvej 9
Copenhagen

See on map

Links
UNIVERSITY OF MAASTRICHT
Netherlands
Address
Minderbroedersberg 4-6
Maastricht

See on map

ABBOTT GMBH& CO.KG
Germany
Address
Knollstraße 50
Ludwigshafen

See on map

GREEK ASSOCIATION OF ALZHEIMER'S DISEASE AND RELATED DISORDERS
Greece
Address
Petrou Syndica 13
Thessaloniki

See on map

ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT
Germany
Address
J5
Mannheim

See on map

FORSCHUNGSZENTRUM JÜLICH GMBH
Germany
Address
Leo Brandt Strasse
Jülich

See on map

LUDWIG MAXIMILIAN UNIVERSITY OF MUNICH CLINIC OF PSYCHIATRY AND PSYCHOTHERAPY
Germany
Address
Nussbaumstr. 7
Munich

See on map